Over the course of the past week, there have been some stocks that have delivered significant gains and one of the biggest movers has been Tykhe Corp (OTCMKTS:HALB). During this run the stock rallied impressively, and managed to deliver gains of as much as 400%. But why?
The rally continued on Thursday as well as the Halberd stock gained 40%. It’s worthwhile for curious investors to take a closer look at Halberd Corporation and the recent developments associated with it.
Tykhe Corp (OTCMKTS:HALB) recently announced that it had applied for a patent for the new category of anti-spike protein monoclonal antibodies which could tackle COVID 19 that it created.
It goes without saying that it is a significant development for Halberd, and the rally in the stock did not come as a surprise.
The above-mentioned discovery was a direct consequence of the research that had been conducted by the company in collaboration with Arizona State University. The intellectual property owned by Halberd has been used by ASU’s Dr. Qiang Chen in order to make the discovery.
The university is going to file the first of many patent applications with regards to the above-mentioned antibody. Scientists at Halberd believe that the antibody could help in ending the COVID 19 pandemic by speeding up the process of identifying the virus.
Halberd is looking to deploy the anti-spike protein monoclonal antibodies in a range of utilizations. The three different utilizations are going to be in the form of treatment, a diagnostic, and a preventive.
Hence, it is quite clear that the full scope of the discovery could eventually result in the launch of a full suite of products that could fight against COVID 19. The excitement about the stock is understandable and investors are adding the Halberd stock to their watch lists to see if this run is sustainable.